Xanthohumol {90000201}

Shared Reference Notes

• [1.1] [#Xanthohumol supplementation] 
  - XN supplementation > decreased plasma insulin concentrations > improved Insulin Resistance. - The intestinal microbiota > metabolizes XN into bioactive compounds, including dihydroxanthohumol > anti-obesity. - XN > increased the relative abundance of three bacteria, Akkermansia muciniphila, Parabacteroides goldsteinii and Alistipes finegoldii.
• [1.2] 
  - some of the positive outcomes of XN are accomplished by increasing #Akkermansia muciniphila, which we also found increased by TXN
• [#Metabolic syndrome] - Xanthohumol (XN) and its derivatives mitigate diet-induced #Obesity-related characteristics of MetS in mice by improving impaired #Glucose and lipid metabolism
• [#Non alcoholic steatohepatitis] - XN and even more so, TXN, attenuates hepatosteatosis by acting as antagonists of PPARγ
• [#Non-alcoholic fatty liver disease] - XN also exhibits hepatoprotective effects in animal models of MAFLD and other liver-damaging conditions
• - TXN treatment also reduced levels of inflammation-inducing microbes, such as #Oscillibacter valericigenes, that lead to adverse metabolic phenotypes.
• - TXN attenuates macrophage inflammatory processes in adipose tissue.

References Notes